Male Hypogonadism Market Share & Industry Growth, 2022

  • Published on

  • View

  • Download


<p>PowerPoint Presentation</p> <p>Male Hypogonadism MarketOpportunities and Forecasts, 2014 - 2022 Pages: 157Published: 2017 </p> <p>MALE HYPOGONADISM MARKETInjectables held the largest market share in 2015. The launch of innovative injectables for the treatment of hypogonadism in men and rise in preference for injections of gonadotropin-releasing hormones over TRT gels &amp; other formulations are expected to drive growth of this drug delivery method.</p> <p>Shubhangi Bawakar</p> <p>Male Hypogonadism Marketreport, published by Allied Market Research forecasts that the global market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% from 2016 to 2022.</p> <p>The pituitary disorders segment accounted for nearly half of the total market share in 2015, and is expected to maintain its dominance during analysis period as well.</p> <p>Male hypogonadism is a clinical condition in which testes cannot produce enough testosterone, resulting in decreased development of muscle mass, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.</p> <p>Growth in the male hypogonadism market is driven by the rise in prevalence &amp; incidence of men with testosterone deficiency, increase in infertility rates, and growth in awareness among the patient population about hypogonadism treatment options by certain campaigns carried out by the government.</p> <p>Read more at :</p> <p>MALE HYPOGONADISM MARKETOVERVIEW</p> <p>PERCENTAGE OF TOTAL POPULATION AGED 65 YEARS &amp; ABOVE BY COUNTRY</p> <p>MALE HYPOGONADISM MARKETKEY BENEFITSThe study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.</p> <p>It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.</p> <p>Extensive analysis by therapy helps in understanding the various types of therapies used to treat hypogonadism.</p> <p>Comprehensive analysis of all geographical regions is provided, which assist in determining the main opportunities in these geographies.</p> <p>Key players within the market are profiled and their strategies are analyzed thoroughly to determine the competitive outlook of the global market.</p> <p>MEXICO MALE HYPOGONADISM MARKET REVENUE</p> <p>By drug therapy, gonadotropin and gonadotropin-releasing hormones therapy segment is projected to grow at the highest CAGR of 8.9% during the forecast period.</p> <p>Pituitary disorders segment is expected to grow at the CAGR of 3.2%.</p> <p>Injectables accounted for nearly half of the market share in 2015.</p> <p>North America accounted for majority of the share (more than three-fourths) in 2015, and is expected to remain dominant throughout the forecast period.</p> <p>U.S. accounted for the majority share in the North American market in 2015, and the Mexican market is expected to grow at the highest CAGR of 6.7%.MALE HYPOGONADISM MARKETKEY FINDINGS</p> <p>KEY PLAYERS IN INDUSTRYAbbVie Inc.Allergan plcAstraZeneca plcBayer AGEli Lilly and Company Ltd.Endo International plcMerck &amp; Co., Inc.Ferring Holding S.A.Finox BiotechIBSA Institut Biochimque SALaboratoires GenevrierTeva Pharmaceutical Industries Ltd.</p> <p>Download Sample Report :</p> <p>MALE HYPOGONADISM MARKET SEGMENTATION</p> <p>MALE HYPOGONADISM MARKETBYGEOGRAPHYNorth America</p> <p>Europe</p> <p>Asia-Pacific</p> <p>LAMEA</p> <p>Follow Us On </p> <p>Thank You!For More Details Visit us at</p> <p></p>


View more >